FDA Peptide Warning Letters April 2026: The Seven-Letter Batch | Artemis Labs
FDA Peptide Warning Letters April 2026: The Seven-Letter Batch
Published August 21, 2026 · Artemis Labs
FDA peptide warning letters April 2026 — The FDA peptide warning letters of April 2026 are seven letters dated March 31, 2026, and posted April 7, 2026, each naming a research-peptide seller. The documented patterns: therapeutic-effect descriptions on product pages, and administration supplies offered in the same shopping cart. FDA held that research-use disclaimers did not control the analysis.
Key findings
- Seven entities, one signature date. All seven letters are dated March 31, 2026, were posted to FDA’s index on April 7, 2026, and name sellers across six states — a coordinated batch, not isolated actions.
- Two documented triggers. Therapeutic-effect descriptions on product pages, and administration supplies offered in the same shopping cart as the compounds — the pairing FDA cited as evidence of intended human use.
- Coded names counted against sellers, not for them. Listings such as “GLP-1 SM” and “GLP-3 RT” were read as circumvention of drug-marketing rules, not as cover.
The seven letters, in one table
Every entity below received a warning letter dated March 31, 2026, posted to FDA’s public index on April 7, 2026.
| Entity | Letter number | Location |
|---|---|---|
| Lovega LLC dba Pink Pony Peptides | 721088 | Wellington, FL |
| Mile High Compounds LLC | 721600 | Clifton, CO |
| Prime Sciences | 721805 | Scottsdale, AZ |
| Gram Peptides | 721806 | Rancho Santa Fe, CA |
| PekCura Labs | 721709 | Pensacola, FL |
| FormPour | 722215 | Canton, MI |
| Guangzhou Huli Technology dba Fantasy Face | 722228 | Chicago, IL |
What triggered the seven-letter batch?
Two patterns recur across the April 2026 letters. First, therapeutic-effect descriptions on product pages: language describing what a compound is claimed to do in a person, sitting on the same page as a research-use disclaimer. Second — and this is the pattern that makes the batch a reference point — administration supplies offered in the same shopping cart as the compounds. FDA cited the composition of the cart itself as evidence: a seller whose checkout pairs research compounds with the means of administering them has, in the agency’s reading, described the intended use without writing a word.
Neither trigger requires an explicit claim. The April 2026 batch establishes that store architecture — what is described, and what is sold alongside what — is itself evidence.
Why coded product names read as circumvention
Several of the seven sellers listed compounds under coded names in place of standard compound nomenclature — “GLP-1 SM” and “GLP-3 RT” are the documented examples. The letters read this coding not as caution but as circumvention: an attempt to market a known drug class while evading the searches and filters that would flag it. For a researcher evaluating vendors, the signal inverts cleanly. A seller that will not name its compounds precisely cannot be verified precisely — no COA can be matched to a compound whose identity is deliberately blurred. Precise nomenclature is a precondition of the verification chain described in our Certificate of Analysis guide.
Is research-use-only labeling a defense?
The April 2026 letters answer this directly. FDA’s stated position: despite disclaimers, “evidence obtained from your website establishes that your products are intended to be drugs for human use.” Labeling, in other words, is one input among many — and it is outweighed whenever the rest of the seller’s footprint contradicts it. A disclaimer beside a therapeutic-effect description, or above a cart that offers administration supplies, does not neutralize either; it coexists with them in a record the agency reads whole.
This is the same totality-of-evidence reasoning FDA applied in December 2024, when a seller’s social-media post was cited alongside its catalog. The April 2026 batch extends it from what a seller says to how a seller’s store is built.
What the batch signals for vendor evaluation
Read as a group, the seven letters mark a shift in scale — seven sites in one day, against four in the December 2024 batch — and a shift in method, from parsing claims to auditing store structure. For researchers, the practical checklist follows from the triggers: a vendor’s product pages should describe compounds in research terms with citations, not effects in people; its cart should contain compounds and documentation, not administration supplies; its compound names should be exact. Our supplier evaluation guide turns these into scoreable criteria, and the batch’s place in the longer sequence of raids, pleas, and shutdowns is charted in the peptide vendor enforcement timeline 2024-2026.
For its part, Artemis Labs structures the store the way the letters demand, not the way they forbid: no administration supplies sold, no dosing or administration content on any page, HPLC purity and mass-spectrometry identity testing by third parties, a COA with every order, and compounds supplied for laboratory research use only — the catalog is built to be audited. Researchers displaced by any of the seven closures or by earlier events can start with the hub on peptide vendor closures 2025-2026.
FAQ
When were the April 2026 FDA peptide warning letters issued?
All seven letters are dated March 31, 2026, and were posted to FDA’s public warning-letter index on April 7, 2026. The two dates matter for records: the letters themselves carry the March date; press and database coverage keys to the April posting date.
Which companies received the April 2026 letters?
Seven sellers: Lovega LLC dba Pink Pony Peptides (721088), Mile High Compounds LLC (721600), Prime Sciences (721805), Gram Peptides (721806), PekCura Labs (721709), FormPour (722215), and Guangzhou Huli Technology dba Fantasy Face (722228) — locations in the table above.
What did FDA say about research-use disclaimers?
That they did not control the outcome. The letters state that despite disclaimers, “evidence obtained from your website establishes that your products are intended to be drugs for human use” — the totality of the site’s evidence outweighed its labeling.
How does this batch differ from the December 2024 letters?
Scale and method. December 10, 2024 brought four letters focused on GLP-1-class catalogs and claim language, including one citation of a company’s social-media post. The April 2026 batch named seven sellers and documented structural triggers — administration supplies in the cart, coded compound names — beyond page copy alone.
References
- FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026. fda.gov
- FDA Warning Letter, Mile High Compounds LLC, 721600-03312026. fda.gov
- FDA Warning Letter, Gram Peptides, 721806-03312026. fda.gov
- FDA Warning Letters index (Prime Sciences, PekCura Labs, FormPour, Guangzhou Huli Technology dba Fantasy Face). fda.gov
- Policy Canary, “FDA research-peptide warning letters, April 2026.” policycanary.io
- The Partnership for Safe Medicines, batch summary PDF (posted April 7, 2026). safemedicines.org
